<DOC>
	<DOC>NCT02040415</DOC>
	<brief_summary>The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to eperisone HCl in efficacy and safety.</brief_summary>
	<brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Eperisone</mesh_term>
	<criteria>Adult males/Females aged over 18 years Patients with symptom of Acute skeletomuscle myospasm and Back pain Patients with Pain VAS Value over 40 mm in Visit 2 Subjects who voluntarily or legal guardian agreed with written consent Patients with Back pain caused by spinal spondylosis, spinal stenosis, fractures, cancer, severe arthritis, osteoporosis, sciatica, infection Muscular patients such as myositis, muscular atrophy disease, increased muscle tone, myasthenia gravis Patients who had taken invasive procedures such as epidural injections or spinal stimulation to cure the back pain within 6 months from the screening point Patients who had taken passive physical therapy or ionphoresis within 12 hours from the screening point Patients with severe GI tract disorder, heart disease, hypertension Patients who had taken NSAIDS within 24hours from the screening point</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>